The World Health Organization(WHO)classification serves as the internationally recognized standard for diagnosing and classifying hematopoietic and lymphoid tissue tumors(WHO-HEAM).Since 2001,it has undergone multiple upgrades and revisions,updating,clarifying,and refining previous tumor diagnostic and classification standards while incorporating numerous new genetic and molecular biological subtypes.In 2022,two classification proposals emerged due to a wealth of clinical and scientific research results:the fifth edition of the WHO hematopoietic and lymphoid tissue classification(WHO-HAEM5),published in Leukemia journal;and the International Consensus Classification(ICC),published in Blood journal.These two schemes differ in their approach to classifying hematopoietic and lymphoid tissue tumors,posing challenges for clinical laboratory diagnosis and treatment.
维普
万方数据